Nicole Carter

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

Thomas F. Durand-Réville, Satenig Guler, Janelle Comita-Prevoir et al. · Nature Microbiology · 2017 · 262 citations

Bacterial Resistance, Antimicrobial Susceptibility, Health Sciences +12

Rational design of a new antibiotic class for drug-resistant infections

Thomas F. Durand-Réville, Alita A. Miller, John P. O’Donnell et al. · Nature · 2021 · 134 citations

Antimicrobial Susceptibility, Antibiotics, Rational Design +8

Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases

Thomas F. Durand-Réville, Janelle Comita-Prevoir, Jing Zhang et al. · Journal of Medicinal Chemistry · 2020 · 59 citations · Full text

Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514

Adam B. Shapiro, Ning Gao, Haris Jahić et al. · ACS Infectious Diseases · 2017 · 58 citations

Bioorganic Chemistry, Antimicrobial Chemotherapy, Chemical Biology +21

Discovery of Pyrazolopyridones as a Novel Class of Gyrase B Inhibitors Using Structure Guided Design

Jason B. Cross, Jing Zhang, Qingyi Yang et al. · ACS Medicinal Chemistry Letters · 2016 · 46 citations · Full text

Combinatorial Chemistry, Drug Target, Bioorganic Chemistry +20